1 |
Xu J, Song J, Yang Z, Zhao J, Wang J, Sun C, Zhu X. Pre-treatment systemic immune-inflammation index as a non-invasive biomarker for predicting clinical outcomes in patients with renal cell carcinoma: a meta-analysis of 20 studies. Biomarkers 2023;:1-14. [PMID: 36598268 DOI: 10.1080/1354750X.2023.2164906] [Reference Citation Analysis]
|
2 |
Zhou Z, Zhou X, Yang Y, Wang L, Wu Z. Pan-Cancer Analysis of Pentraxin 3: A Potential Biomarker of COVID-19. Cancers 2022;14:4438. [DOI: 10.3390/cancers14184438] [Reference Citation Analysis]
|
3 |
Huang W, Hickson LJ, Eirin A, Kirkland JL, Lerman LO. Cellular senescence: the good, the bad and the unknown. Nat Rev Nephrol 2022. [PMID: 35922662 DOI: 10.1038/s41581-022-00601-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
4 |
Reddy R, Mintz J, Golan R, Firdaus F, Ponce R, Van Booven D, Manoharan A, Issa I, Blomberg BB, Arora H. Antibody Diversity in Cancer: Translational Implications and Beyond. Vaccines 2022;10:1165. [DOI: 10.3390/vaccines10081165] [Reference Citation Analysis]
|
5 |
Rahmati Nezhad P, Riihilä P, Knuutila JS, Viiklepp K, Peltonen S, Kallajoki M, Meri S, Nissinen L, Kähäri VM. Complement Factor D Is a Novel Biomarker and Putative Therapeutic Target in Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2022;14:305. [PMID: 35053469 DOI: 10.3390/cancers14020305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|